ORION CORPORATION PRESS RELEASE 23 OCTOBER 2025 at 15:30 EEST Orion and Abzena announce exclusive commercial license for Abzena’s antibody Orion Corporation (“Orion”) and Abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjugates, today announced that Orion has obtained an exclusive, focused commercial license to one of Abzena’s monoclonal antibodies (mAbs) that targets a cancer of high clinical unmet need. The antibody will strengthen Orion’s broad oncology-focused drug Research ...

Key Takeaways DHR is set to report Q3 2025 results on Oct. 21, with revenues estimated at $6.00 billion.Life Sciences may face softness, while Biotechnology gains from strong bioprocessing demand.Diagnostics likely grew modestly, aided by the Beckman Coulter unit and steady clinical demand.Danaher Corporation (DHR) is scheduled to release third-quarter 2025 results on Oct. 21, before market open.The Zacks Consensus Estimate for revenues is pegged at $6.00 billion, which indicates an increase of 3.4% from th ...

Key Takeaways Biotech core revenues rose 6% YoY in Q2, led by strong bioprocessing demand.Orders in bioprocessing are up for eight straight quarters, signaling solid momentum.Discovery and medical sales declined on weaker research equipment demand.Danaher Corporation’s (DHR) Biotechnology segment continues to play an important role in its overall growth. In the second quarter of 2025, the segment’s core revenues rose 6% on a year-over-year basis, fueled by sustained momentum in the bioprocessing business.An ...

Key Takeaways DHR's bioprocessing orders rose for the eighth straight quarter in Q2 2025.Biotechnology segment revenues grew 6%, driven by demand for mAbs.Life Sciences revenues fell 2.5% as academic and government demand weakened.Danaher Corporation (DHR) has been witnessing solid momentum in its bioprocessing business, driven by an increase in demand for consumables from large pharmaceutical customers in Europe. In the second quarter of 2025, orders in the bioprocessing business increased for the eighth c ...